Literature DB >> 8751400

Usefulness of tumor volumetry by magnetic resonance imaging in assessing response to radiation therapy in carcinoma of the uterine cervix.

N A Mayr1, V A Magnotta, J C Ehrhardt, J A Wheeler, J I Sorosky, B C Wen, C S Davis, R E Pelsang, B Anderson, J F Doornbos, D H Hussey, W T Yuh.   

Abstract

PURPOSE: Clinical evaluation of tumor size in cervical cancer is often difficult, and clinical signs of radiation therapy failure may not be present until well after completion of treatment. The purpose of this study is to investigate early indicators of treatment response using magnetic resonance (MR) imaging for quantitative assessment of tumor volume and tumor regression rate before, during, and after radiation therapy. METHODS AND MATERIALS: Thirty-four patients with cervical cancer Stages IB [5], IIB [8], IIIA [1], IIIB [14], IVA [3], IVB [1], and recurrent [2] were studied prospectively with four serial MR examinations obtained at the start of radiation therapy, at 2-2.5 weeks (20-24 Gy), at 4-5 weeks (40-50 Gy), and 1-2 months after treatment completion. Tumor volume was assessed by three-dimensional volumetric measurements using T2-weighted images of each MR examination. The volume regression rate was generated based on the four sequential MR studies. These findings were correlated with local control, metastasis rate, and disease-free survival. Median follow-up was 18 months (range: 9-43 months).
RESULTS: The tumor regression rate after a dose of 40-50 Gy correlated significantly with treatment outcome. The actuarial 2-year disease-free survival was 88.4% in patients with tumors regressing to < 20% of the initial volume compared with 45.4% in those with > or = 20% residual (p = 0.007). The incidence of local recurrence was 9.5% (2 out of 21) and 76.9% (10 out of 13), respectively (p < 0.001). Analysis by initial tumor volume showed that this observation was valid in patients with initial volumes between 40 and 100 cm3. Analysis by FIGO stage confirmed this observation in all patients except those with Stage IB.
CONCLUSION: Sequential tumor volumetry using MR imaging appears to be a sensitive measure of the responsiveness of cervical cancer to irradiation. Treatment response can be assessed as early as during the course of radiation therapy by measurement of initial tumor volume and regression rate at 40-50 Gy. In patients with large (> 40 cm3) and advanced (Stage > or = IIIA) tumors, this technique may be helpful in supplementing the clinical examination for response assessment. The identification of patients at high risk for treatment failure may ultimately lead to improved clinical outcome.

Entities:  

Mesh:

Year:  1996        PMID: 8751400     DOI: 10.1016/0360-3016(96)00230-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  19 in total

1.  Volume Measurement by Diffusion-Weighted Imaging in Cervical Cancer.

Authors:  Shinya Fujii; Naoki Iwata; Chie Inoue; Naoko Mukuda; Takeru Fukunaga; Toshihide Ogawa
Journal:  Yonago Acta Med       Date:  2017-06-26       Impact factor: 1.641

2.  Sequential magnetic resonance imaging of cervical cancer: the predictive value of absolute tumor volume and regression ratio measured before, during, and after radiation therapy.

Authors:  Jian Z Wang; Nina A Mayr; Dongqing Zhang; Kaile Li; John C Grecula; Joseph F Montebello; Simon S Lo; William T C Yuh
Journal:  Cancer       Date:  2010-11-01       Impact factor: 6.860

3.  Palliative Hypofractionated Radiotherapy For Non-small-cell Lung Cancer (NSCLC) Patients Previously Treated By Induction Chemotherapy.

Authors:  George A Plataniotis; Maria-Aikaterini Theofanopoulou; Konstantinia Sotiriadou; Kyriaki Theodorou; Panagiotis Mavroidis; George Kyrgias
Journal:  J Thorac Dis       Date:  2009-12       Impact factor: 2.895

4.  Onset time of tumor repopulation for cervical cancer: first evidence from clinical data.

Authors:  Zhibin Huang; Nina A Mayr; Mingcheng Gao; Simon S Lo; Jian Z Wang; Guang Jia; William T C Yuh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-02       Impact factor: 7.038

5.  Ultra-early predictive assay for treatment failure using functional magnetic resonance imaging and clinical prognostic parameters in cervical cancer.

Authors:  Nina A Mayr; William T C Yuh; David Jajoura; Jian Z Wang; Simon S Lo; Joseph F Montebello; Kyle Porter; Dongqing Zhang; D Scott McMeekin; John M Buatti
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

6.  Prognostic value of tumor volume in nasopharyngeal carcinoma.

Authors:  Jeong-Hyun Kim; Joon-Kyoo Lee
Journal:  Yonsei Med J       Date:  2005-04-30       Impact factor: 2.759

7.  Translating response during therapy into ultimate treatment outcome: a personalized 4-dimensional MRI tumor volumetric regression approach in cervical cancer.

Authors:  Nina A Mayr; Jian Z Wang; Simon S Lo; Dongqing Zhang; John C Grecula; Lanchun Lu; Joseph F Montebello; Jeffrey M Fowler; William T C Yuh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-07-23       Impact factor: 7.038

8.  Pre- and post-radiotherapy MRI results as a predictive model for response in laryngeal carcinoma.

Authors:  Redina Ljumanovic; Johannes A Langendijk; Otto S Hoekstra; Dirk L Knol; C René Leemans; Jonas A Castelijns
Journal:  Eur Radiol       Date:  2008-05-20       Impact factor: 5.315

9.  Predicting outcomes in cervical cancer: a kinetic model of tumor regression during radiation therapy.

Authors:  Zhibin Huang; Nina A Mayr; William T C Yuh; Simon S Lo; Joseph F Montebello; John C Grecula; Lanchun Lu; Kaile Li; Hualin Zhang; Nilendu Gupta; Jian Z Wang
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

10.  Dynamic contrast-enhanced and diffusion-weighted MRI for early detection of tumoral changes in single-dose and fractionated radiotherapy: evaluation in a rat rhabdomyosarcoma model.

Authors:  F De Keyzer; V Vandecaveye; H Thoeny; F Chen; Y Ni; G Marchal; R Hermans; S Nuyts; W Landuyt; H Bosmans
Journal:  Eur Radiol       Date:  2009-06-06       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.